Volociximab

Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.^[1]

Volociximab

Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	α5β1 integrin
Clinical data
ATC code	none
Identifiers
CAS Number	558480-40-3 N
ChemSpider	none
UNII	496K5Z02NW
KEGG	D06319 Y
Chemical and physical data
Formula	C6434H9942N1706O2040S52
Molar mass	145501.33 g·mol−1
NY (what is this?)  (verify)

It is thought to reduce metastases. Early results show potential in renal cell cancers.^{[citation needed]}